Information Related to Clinical Trials
TaiRx’s novel anti-cancer drug CVM-1118 is currently in Phase II clinical program.
If you would like to learn more information regarding the clinical trials, please contact the nearest clinical trial center.
News
TaiRx’s sodium selenite pentahydrate—SelenOne®—earned the Symbol of National Quality (SNQ) in 2022 for its affirmed safety and quality for use as a food additive.
2022/12/23 In December 2022, TaiRx’s proprietary sodium selenite pentahydrate, [...]
Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.
2020/12/9 Andrew Lin received his master’s degree of Business [...]
TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.
2020/12/1 Having been awarded the 12th National Innovation Award [...]